Defatting of Human Livers During Long-Term e x situ Normothermic Perfusion: Novel Strategy to Rescue Discarded Organs for Transplantation.
Journal
Annals of surgery
ISSN: 1528-1140
Titre abrégé: Ann Surg
Pays: United States
ID NLM: 0372354
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
medline:
23
10
2023
pubmed:
27
7
2023
entrez:
27
7
2023
Statut:
ppublish
Résumé
To develop a protocol for the defatting of steatotic liver grafts during long-term ex situ normothermic machine perfusion. Despite the alarming increase in donor organ shortage, the highly prevalent fatty liver grafts are often discarded due to the risk of primary nonfunction. Effective strategies preventing such outcomes are currently lacking. An exciting new avenue is the introduction of ex situ normothermic machine perfusion (NMP), enabling a liver to remain fully functional for up to 2 weeks and providing a unique window of opportunity for defatting before transplantation. Over a 5-year period, 23 discarded liver grafts and 28 partial livers from our resection program were tested during ex situ normothermic machine perfusion. The steatosis degree was determined on serial biopsies by expert pathologists, and triglyceride contents were measured simultaneously. Of 51 liver grafts, 20 were steatotic, with up to 85% macrovesicular steatosis, and were perfused for up to 12 days. Ten livers displayed marked (5 of which almost complete) loss of fat, while the other 10 did not respond to long-term perfusion. Successful defatting was related to prolonged perfusion, automated glucose control, circadian nutrition, and L-carnitine/fenofibrate supplementation. Pseudopeliotic steatosis and the associated activation of Kupffer/stellate cells were unexpected processes that might contribute to defatting. Synthetic and metabolic functions remained preserved for most grafts until perfusion ended. Ex situ long-term perfusion effectively reduces steatosis while preserving organ viability and may in the future allow transplantation of primarily unusable high-risk grafts, significantly increasing the number of organs available for transplantation.
Sections du résumé
OBJECTIVE
To develop a protocol for the defatting of steatotic liver grafts during long-term ex situ normothermic machine perfusion.
BACKGROUND
Despite the alarming increase in donor organ shortage, the highly prevalent fatty liver grafts are often discarded due to the risk of primary nonfunction. Effective strategies preventing such outcomes are currently lacking. An exciting new avenue is the introduction of ex situ normothermic machine perfusion (NMP), enabling a liver to remain fully functional for up to 2 weeks and providing a unique window of opportunity for defatting before transplantation.
METHODS
Over a 5-year period, 23 discarded liver grafts and 28 partial livers from our resection program were tested during ex situ normothermic machine perfusion. The steatosis degree was determined on serial biopsies by expert pathologists, and triglyceride contents were measured simultaneously.
RESULTS
Of 51 liver grafts, 20 were steatotic, with up to 85% macrovesicular steatosis, and were perfused for up to 12 days. Ten livers displayed marked (5 of which almost complete) loss of fat, while the other 10 did not respond to long-term perfusion. Successful defatting was related to prolonged perfusion, automated glucose control, circadian nutrition, and L-carnitine/fenofibrate supplementation. Pseudopeliotic steatosis and the associated activation of Kupffer/stellate cells were unexpected processes that might contribute to defatting. Synthetic and metabolic functions remained preserved for most grafts until perfusion ended.
CONCLUSION
Ex situ long-term perfusion effectively reduces steatosis while preserving organ viability and may in the future allow transplantation of primarily unusable high-risk grafts, significantly increasing the number of organs available for transplantation.
Identifiants
pubmed: 37497663
doi: 10.1097/SLA.0000000000006047
pii: 00000658-202311000-00006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
669-675Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Zarrinpar A, Busuttil RW. Liver transplantation: past, present and future. Nat Rev Gastroenterol Hepatol. 2013;10:434–440.
Bodzin AS, Baker TB. Liver transplantation today: where we are now and where we are going. Liver Transpl. 2018;24:1470–1475.
Ivanics T, Abreu P, De Martin E, et al. Changing Trends in liver transplantation: challenges and solutions. Transplantation. 2021;105:743–756.
Su F, Yu L, Berry K, et al. Aging of liver transplant registrants and recipients: trends and impact on waitlist outcomes, post-transplantation outcomes, and transplant-related survival benefit. Gastroenterology. 2016;150:441–53 e6.
Mousa OY, Nguyen JH, Ma Y, et al. Evolving role of liver transplantation in elderly recipients. Liver Transpl. 2019;25:1363–1374.
Durand F, Levitsky J, Cauchy F, et al. Age and liver transplantation. J Hepatol. 2019;70:745–758.
Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–1606.
Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: The State of the Disease. Gastroenterology. 2020;158:1851–1864.
Sousa Da Silva RX, Muellhaupt B, Dutkowski P, et al. Liver transplantation for malignant liver tumors. iLIVER. 2022;1:3–11.
Eden J, Sousa Da Silva RX, Cortes-Cerisuelo M, et al. Utilization of livers donated after circulatory death for transplantation - An international comparison. J Hepatol. 2023.
McCormack L, Dutkowski P, El-Badry AM, et al. Liver transplantation using fatty livers: always feasible? J Hepatol. 2011;54:1055–1062.
Moctezuma-Velazquez C, Marquez-Guillen E, Torre A. Obesity in the Liver Transplant Setting. Nutrients. 2019;11:2552–2570.
van Rijn R, Schurink IJ, de Vries Y, et al. Hypothermic machine perfusion in liver transplantation - A Randomized Trial. N Engl J Med. 2021;384:1391–1401.
Schlegel A, Mueller M, Muller X, et al. A multicenter randomized-controlled trial of hypothermic oxygenated perfusion (HOPE) for human liver grafts before transplantation. J Hepatol. 2023;78:783–793.
Martins PN, Buchwald JE, Mergental H, et al. The role of normothermic machine perfusion in liver transplantation. Int J Surg. 2020;82S:52–60.
Nasralla D, Coussios CC, Mergental H, et al. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557:50–56.
Mergental H, Laing RW, Kirkham AJ, et al. Transplantation of discarded livers following viability testing with normothermic machine perfusion. Nat Commun. 2020;11:2939.
Markmann JF, Vagefi PA, MacConmara MP. Normothermic machine perfusion increases donor liver use. JAMA Surg. 2022;157:742–743.
Quintini C, Del Prete L, Simioni A, et al. Transplantation of declined livers after normothermic perfusion. Surgery. 2022;171:747–756.
Michalopoulos GK. Liver regeneration. J Cell Physiol. 2007;213:286–300.
Eshmuminov D, Becker D, Bautista Borrego L, et al. An integrated perfusion machine preserves injured human livers for 1 week. Nat Biotechnol. 2020;38:189–198.
Mueller M, Hefti M, Eshmuminov D, et al. Long-term normothermic machine preservation of partial livers: First experience with 21 human hemi-livers. Ann Surg. 2021;274:836–842.
Clavien PA, Dutkowski P, Mueller M, et al. Transplantation of a human liver following 3 days of ex situ normothermic preservation. Nat Biotechnol. 2022;40:1610–1616.
Liu Q, Nassar A, Buccini L, et al. Lipid metabolism and functional assessment of discarded human livers with steatosis undergoing 24 hours of normothermic machine perfusion. Liver Transpl. 2018;24:233–245.
Boteon YL, Attard J, Boteon A, et al. Manipulation of lipid metabolism during normothermic machine perfusion: effect of defatting therapies on donor liver functional recovery. Liver Transpl. 2019;25:1007–1022.
Patrono D, De Carlis R, Gambella A, et al. Viability assessment and transplantation of fatty liver grafts using end-ischemic normothermic machine perfusion. Liver Transpl. 2022;29:508–520.
Neil DAH, Minervini M, Smith ML, et al. Banff consensus recommendations for steatosis assessment in donor livers. Hepatology. 2022;75:1014–1025.
Nagino M, DeMatteo R, Lang H, et al. Proposal of a new comprehensive notation for hepatectomy: The “New World” Terminology. Ann Surg. 2021;274:1–3.
Deng J, Han Z, Tang H, et al. Elevated fasting glucose level increases the risk of fatty liver disease: a 10-year study of 31,154 individuals. BMC Gastroenterol. 2022;22:521.
Ling Q, Chen J, Liu X, et al. The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: a dose-response meta-analysis. Front Endocrinol (Lausanne). 2022;13:1043169.
Martini T, Naef F, Tchorz JS. Spatiotemporal metabolic liver zonation and consequences on pathophysiology. Annu Rev Pathol. 2023;18:439–466.
Jiang F, Zhang Z, Zhang Y, et al. L-carnitine ameliorates the liver inflammatory response by regulating carnitine palmitoyltransferase I-dependent PPARgamma signaling. Mol Med Rep. 2016;13:1320–1328.
Rankin EB, Rha J, Selak MA, et al. Hypoxia-inducible factor 2 regulates hepatic lipid metabolism. Mol Cell Biol. 2009;29:4527–4538.
Ferrell L, Bass N, Roberts J, et al. Lipopeliosis: fat induced sinusoidal dilatation in transplanted liver mimicking peliosis hepatis. J Clin Pathol. 1992;45:1109–1110.
Bioulac-Sage P, Balabaud C, Ferrell L. Lipopeliosis revisited: should we keep the term? Am J Surg Pathol. 2002;26:134–135.
Sousa Da Silva RX, Weber A, Dutkowski P, et al. Machine perfusion in liver transplantation. Hepatology. 2022;76:1531–1549.
Mazilescu LI, Selzner M, Selzner N. Defatting strategies in the current era of liver steatosis. JHEP Rep. 2021;3:100265.
Eggenhofer E, Groell A, Junger H, et al. Steatotic livers are more susceptible to ischemia reperfusion damage after transplantation and show increased gammadelta T Cell infiltration. Int J Mol Sci. 2021;22:2036–2047.
Lu Q, Tian X, Wu H, et al. Metabolic changes of hepatocytes in NAFLD. Front Physiol. 2021;12:710420.
Paris J, Henderson NC. Liver zonation, revisited. Hepatology. 2022;76:1219–1230.
Villar VH, Allega MF, Deshmukh R, et al. Hepatic glutamine synthetase controls N(5)-methylglutamine in homeostasis and cancer. Nat Chem Biol. 2022;19:292–300.
Hessheimer AJ, Cardenas A, Garcia-Valdecasas JC, et al. Can we prevent ischemic-type biliary lesions in donation after circulatory determination of death liver transplantation? Liver Transpl. 2016;22:1025–1033.